@samcro. Don't understand why we would need a " safety net". Rap is well on track with their de novo submissions to FDA. FDA does not control the " marketing " of the algorithm. FDA will provide the gold standard that resapp seeks. It makes no difference to the use in Europe, Asia, Australia etc but it will make the algorithm more widely accepted by the medical community, and give the algorithm a more prestigious name. Rap are seeking FDA approval because the biggest market for Telehealth is the US. Management have already employed Experien Group to act as a safety net. Management have set out marketing strategies . You will probably get a better idea reading a Rap newsletter about their marketing strategy than reading a newsletter from another company. So it was a cross promotion. GL with your other investments which you are promoting , you won't need it with RAP.
RAP Price at posting:
46.5¢ Sentiment: Buy Disclosure: Held
